BR112019003731A2 - aplicação de pridopidina para tratamento de distonias - Google Patents

aplicação de pridopidina para tratamento de distonias

Info

Publication number
BR112019003731A2
BR112019003731A2 BR112019003731A BR112019003731A BR112019003731A2 BR 112019003731 A2 BR112019003731 A2 BR 112019003731A2 BR 112019003731 A BR112019003731 A BR 112019003731A BR 112019003731 A BR112019003731 A BR 112019003731A BR 112019003731 A2 BR112019003731 A2 BR 112019003731A2
Authority
BR
Brazil
Prior art keywords
pridopidine
dystonias
treatment
application
individual
Prior art date
Application number
BR112019003731A
Other languages
English (en)
Inventor
Borowsky Beth
Eyal Eli
D Grachev Igor
Savola Juha-Matti
Forrest Gordon Mark
Hayden Michael
Papapetropoulos Spyridon
Original Assignee
Prilenia Therapeutics Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Therapeutics Dev Ltd filed Critical Prilenia Therapeutics Dev Ltd
Publication of BR112019003731A2 publication Critical patent/BR112019003731A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

aplicação de pridopidina para tratamento de distonias a invenção fornece um método de tratamento de um indivíduo afligido com uma distonia, compreendendo a administração, de maneira periódica, ao indivíduo, de uma composição farmacêutica compreendendo uma quantidade de pridopidina eficaz para tratar o indivíduo.
BR112019003731A 2016-08-24 2017-08-24 aplicação de pridopidina para tratamento de distonias BR112019003731A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662379175P 2016-08-24 2016-08-24
US201662395319P 2016-09-15 2016-09-15
PCT/US2017/048458 WO2018039475A1 (en) 2016-08-24 2017-08-24 Use of pridopidine for treating dystonias

Publications (1)

Publication Number Publication Date
BR112019003731A2 true BR112019003731A2 (pt) 2019-07-16

Family

ID=61246309

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019003731A BR112019003731A2 (pt) 2016-08-24 2017-08-24 aplicação de pridopidina para tratamento de distonias

Country Status (9)

Country Link
US (2) US11826361B2 (pt)
EP (1) EP3503890A4 (pt)
JP (2) JP7278210B2 (pt)
CN (1) CN110012661A (pt)
AU (1) AU2017315781B2 (pt)
BR (1) BR112019003731A2 (pt)
CA (1) CA3035099C (pt)
MX (1) MX2019002190A (pt)
WO (1) WO2018039475A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140008297A (ko) 2010-09-03 2014-01-21 아이백스 인터내셔널 게엠베하 도파민성 안정제로서 유용한 프리도피딘의 듀테륨화된 유사체
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
AU2014281414A1 (en) 2013-06-21 2016-01-21 Teva Pharmaceuticals International Gmbh Use of high dose pridopidine for treating Huntington's disease
EP4282479A3 (en) 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
MX2019002190A (es) 2016-08-24 2019-09-11 Prilenia Therapeutics Dev Ltd Uso de pridopidina para tratar distonías.
CN109923102B (zh) 2016-08-24 2022-11-15 普瑞尼亚神经治疗有限公司 普利多匹定用于治疗功能下降的用途
WO2019050775A1 (en) 2017-09-08 2019-03-14 Teva Pharmaceuticals International Gmbh PRIDOPIDINE FOR THE TREATMENT OF DYSKINESIC INDUCED BY A MEDICINAL PRODUCT

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
DK1773772T3 (da) * 2004-06-08 2010-09-13 Nsab Af Neurosearch Sweden Ab Nye disubstituerede phenylpiperidiner/piperaziner som modulatorer af dopaminneurotransmission
SE0401465D0 (sv) * 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
DK1802573T3 (en) 2004-10-13 2016-12-19 Teva Pharmaceuticals Int Gmbh METHOD OF SYNTHESIS OF 4- (3-METHANSULPHONYLPHENYL) -1-N-PROPYL-PIPERIDINE.
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
PT2146961E (pt) 2007-04-12 2014-04-30 Ivax Int Gmbh Derivados de n-óxido e/ou di-n-óxido de estabilizadores / moduladores dos recetores da dopamina exibindo perfis de efeitos secundários cardiovasculares melhorados
US8562488B2 (en) * 2009-10-05 2013-10-22 The Cleveland Clinic Foundation Systems and methods for improving motor function with assisted exercise
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
KR20140008297A (ko) 2010-09-03 2014-01-21 아이백스 인터내셔널 게엠베하 도파민성 안정제로서 유용한 프리도피딘의 듀테륨화된 유사체
BR112014005389A8 (pt) 2011-09-07 2018-04-03 Ivax Int Gmbh Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal
TWI579272B (zh) 2011-12-08 2017-04-21 梯瓦製藥國際有限責任公司 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
KR20150013476A (ko) 2012-04-04 2015-02-05 아이백스 인터내셔널 게엠베하 조합요법용 약학적 조성물
US20140037850A1 (en) * 2012-08-06 2014-02-06 General Electric Company Corrosion and wear resistant organic coatings
AU2014281414A1 (en) * 2013-06-21 2016-01-21 Teva Pharmaceuticals International Gmbh Use of high dose pridopidine for treating Huntington's disease
CA2937243C (en) * 2014-01-22 2023-07-18 Teva Pharmaceuticals International Gmbh Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
EP4282479A3 (en) 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
US20170020854A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
WO2017147366A1 (en) 2016-02-24 2017-08-31 Teva Pharmaceuticals International Gmbh Treatment of neurodegenerative eye disease using pridopidine
CN109923102B (zh) 2016-08-24 2022-11-15 普瑞尼亚神经治疗有限公司 普利多匹定用于治疗功能下降的用途
MX2019002190A (es) 2016-08-24 2019-09-11 Prilenia Therapeutics Dev Ltd Uso de pridopidina para tratar distonías.
JP2019529411A (ja) 2016-09-15 2019-10-17 プリレニア ニューロセラピューティクス リミテッド 不安症およびうつ病の治療のためのプリドピジンの使用
WO2018053280A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating rett syndrome
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
DK3570940T3 (da) 2017-01-20 2024-02-19 Prilenia Neurotherapeutics Ltd Pridopidin til anvendelse i behandling af fragilt x-syndrom
EP3668509B1 (en) 2017-08-14 2022-11-16 Prilenia Neurotherapeutics Ltd. Method of treating amyotrophic lateral sclerosis with pridopidine
WO2019050775A1 (en) 2017-09-08 2019-03-14 Teva Pharmaceuticals International Gmbh PRIDOPIDINE FOR THE TREATMENT OF DYSKINESIC INDUCED BY A MEDICINAL PRODUCT

Also Published As

Publication number Publication date
JP7278327B2 (ja) 2023-05-19
EP3503890A4 (en) 2020-05-06
CA3035099A1 (en) 2018-03-01
JP7278210B2 (ja) 2023-05-19
WO2018039475A1 (en) 2018-03-01
CA3035099C (en) 2023-01-17
JP2021119189A (ja) 2021-08-12
US20240075021A1 (en) 2024-03-07
AU2017315781A1 (en) 2019-04-11
WO2018039475A8 (en) 2018-10-04
US20190192496A1 (en) 2019-06-27
EP3503890A1 (en) 2019-07-03
MX2019002190A (es) 2019-09-11
US11826361B2 (en) 2023-11-28
JP2019524897A (ja) 2019-09-05
CN110012661A (zh) 2019-07-12
AU2017315781B2 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
BR112019003731A2 (pt) aplicação de pridopidina para tratamento de distonias
BR112017020895A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
CR20170359A (es) Oligómetros antisentido de tau y usos de estos
CL2016001715A1 (es) Nuevos inhibidores de glutaminasa
BR112018003588A2 (pt) compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk
BR112016022855A2 (pt) composições e métodos para modular a expressão de pkk
EA201792496A1 (ru) Способы лечения воспаления или нейропатической боли
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
BR112017011900A2 (pt) tratamento de ataques com fosfatase alcalina recombinante
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
PH12019501097A1 (en) Magl inhibitors
CR20160582A (es) Composición para tratar diabetes, que contienen un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
BR112017000470A2 (pt) composto, composição farmacêutica, método para modular atividade, método para tratar uma afecção
PH12019501102A1 (en) Magl inhibitors
BR112016017041A2 (pt) Proteína isolada tendo atividade de fosfatase, polinucleotídeo, vetor, célula hospedeira, método para produzir uma proteína e composição
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
BR112017009584A2 (pt) tratamento de retinite pigmentosa com n-acetilcisteína amida
BR112018009311A8 (pt) ?método para tratar um sujeito humano sofrendo de tma persistente associada com transplante de célula tronco hematopoiética?
ECSP19057403A (es) Usos terapéuticos de un polvo de insectos
BR112021018456A2 (pt) Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento
CL2020000085A1 (es) Moduladores de nlrp3.
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
BR112019024566A2 (pt) inibidores de pirazol magl
BR112019023948A2 (pt) tratamento de cistos epiteliais por injeção intracística de partículas antineoplásicas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25D Requested change of name of applicant approved

Owner name: PRILENIA NEUROTHERAPEUTICS LTD. (IL)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: VIDE PARECER.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]